Systemic Lupus Erythematosus (SLE)NCT07083622
Efficacy of Vitamin C Supplementation on Malondialdehid Levels and Disease Activity in SLE Patients
A study testing Vitamin C in people with Systemic Lupus Erythematosus (SLE), run by Universitas Sriwijaya at 1 site in Indonesia.
Trial summary
The study aimed to evaluate the efficacy of vitamin C supplementation compared to placebo towards malondialdehid levels and disease activity with the MEX-SLEDAI score in Systemic Lupus Erythematosus (SLE) patients. The current study was designed as a single-center double-blind randomized controlled clinical trial. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Systemic Lupus Erythematosus (SLE)
- What is being tested?
- Vitamin C
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 38 participants
- Where
- 1 siteIndonesia
- Study dates
- 1 Sep 2024to 30 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients diagnosed with mild to moderate systemic lupus erythematosus (SLE).
- Patients aged over 18 years.
- Willing to participate in the study by signing an informed consent form.
Who cannot join
- Pregnant or breastfeeding patients.
- Patients currently taking vitamin C supplementation within the past 3 days.
- Patients with other immune-related disorders, either autoimmune or immunocompromised conditions, such as Human Immunodeficiency Virus (HIV) infection.
- Patients with comorbid diseases.
- Patients diagnosed with severe SLE or those who have achieved remission.
- Patients with hemochromatosis.
Show all 13Show fewer
- Patients with a history of kidney stones.
- Drop-Out Criteria
- Death before the completion of the study.
- Patients who stop taking the study medication for more than 3 weeks.
- Occurrence of severe side effects or worsening of the disease.
- Hospitalization or symptom worsening during the intervention period.
- Loss to follow-up.
Trial locations and contacts
1 site in 1 country.
Indonesia1 site
Mohammad Hoesin General Hospital
Palembang, South Sumatera, 30126
About this study
Official title: The Efficacy of Vitamin C Supplementation on Malondialdehid Levels and Disease Activity in Systemic Lupus Erythematosus Patients
The study aimed to evaluate the efficacy of vitamin C supplementation compared to placebo towards malondialdehid levels and disease activity with the MEX-SLEDAI score in Systemic Lupus Erythematosus (SLE) patients. The current study was designed as a single-center double-blind randomized controlled clinical trial. The participants were voluntarily recruited ≥ 18 years old SLE patients, with mild to moderate disease activity and did not consumed vitamin C 1 week prior to the trial study. Participants were randomized into two groups receiving vitamin C supplementation, or placebo. Malondialdehid levels and MEX-SLEDAI score were evaluated at the beginning and at the end of the 8 week trial for analysis.
Read the detailed description
This research is a double blind randomized controlled trial study. The study subjects were 38 patients diagnosed with mild to moderate lupus activity, randomly divided into 2 groups, who received vitamin C supplementation twice daily for 8 weeks and the group that received placebo. Serum malondialdehid levels and the degree of disease activity using MEX-SLEDAI score were measured before and after treatment.
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Being tested
- Vitamin C, Placebo
- Keywords
- systemic lupus erythematosus, SLE, vitamin c, Malondialdehid, Mex-SLEDAI, disease activity
- Medical subject headings
- Lupus Erythematosus, Systemic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin CDietary supplement
The patients received vitamin C supplementation
PlaceboDietary supplement
Patients received placebo capsules
| Study group | Role | What they receive |
|---|---|---|
| Vitamin C | Experimental | The patients were given a tablet containing Vitamin C 500 mg twice a day Receives: Dietary Supplement: Vitamin C |
| Placebo | Placebo comparator | The patients were given a placebo capsule with a similar color, shape, size and taste twice a day Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
MEX-SLEDAI
To determine the effectiveness of adding vitamin C compared to placebo towards disease activity in SLE patients, measured with MEX-SLEDAI score
Measured: From enrollment to the end of the treatment at 8 weeks
Malondialdehid
To determine the effectiveness of adding vitamin C compared to placebo towards malondialdehid levels concentration change in SLE patients.
Measured: From enrollment to the end of the treatment at 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2025
- Study start1 Sep 2024
- Primary completion30 Nov 2024
- Study completion30 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Systemic Lupus Erythematosus (SLE)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study was The study was designed as a single-center double-blind randomized controlled clinical trial. Participants were randomized into two groups receiving Vitamin C or placebo
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 38 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universitas Sriwijaya
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yuniza, Universitas Sriwijaya
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07083622
- Sponsor's protocol ID
- DP0403DXVIII0608ETIK2392024
- Status last verified
- Jul 2025
- First submitted
- 1 Jul 2025
- Last updated
- 24 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Bojanic, Z. et al. Effects of Methylprednisolone and Vitamin C Therapy on Malondialdehyde Level in Patients With Systemic Lupus Erythematosus. Acta Medica Median. 49, 10-15 (2010).
Minami Y, Sasaki T, Arai Y, Kurisu Y, Hisamichi S. Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients. J Rheumatol. 2003 Apr;30(4):747-54.
PubMed 12672194Atik N, Putri Pratiwi S, Hamijoyo L. Correlation between C-reactive Protein with Malondialdehyde in Systemic Lupus Erythematosus Patients. Int J Rheumatol. 2020 Jul 1;2020:8078412. doi: 10.1155/2020/8078412. eCollection 2020.
PubMed 32695177
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy of Vitamin C Supplementation on Malondialdehid Levels and Disease Activity in Systemic Lupus Erythematosus Patients
- ClinicalTrials.gov ID
- NCT07083622
- Acronym / sponsor ID
- DP0403DXVIII0608ETIK2392024
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Keywords
- systemic lupus erythematosus, SLE, vitamin c, Malondialdehid, Mex-SLEDAI, disease activity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 38 participants (actual)
- Lead sponsor
- Universitas SriwijayaUniversity, hospital or other
- Study start
- 1 Sep 2024 (actual)
- Primary completion
- 30 Nov 2024 (actual)
- Study completion
- 30 Nov 2024 (actual)
- First posted
- 24 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aimed to evaluate the efficacy of vitamin C supplementation compared to placebo towards malondialdehid levels and disease activity with the MEX-SLEDAI score in Systemic Lupus Erythematosus (SLE) patients. The current study was designed as a single-center double-blind randomized controlled clinical trial. The participants were voluntarily recruited ≥ 18 years old SLE patients, with mild to moderate disease activity and did not consumed vitamin C 1 week prior to the trial study. Participants were randomized into two groups receiving vitamin C supplementation, or placebo. Malondialdehid levels and MEX-SLEDAI score were evaluated at the beginning and at the end of the 8 week trial for analysis.
Detailed description
This research is a double blind randomized controlled trial study. The study subjects were 38 patients diagnosed with mild to moderate lupus activity, randomly divided into 2 groups, who received vitamin C supplementation twice daily for 8 weeks and the group that received placebo. Serum malondialdehid levels and the degree of disease activity using MEX-SLEDAI score were measured before and after treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
- Model description
- The study was The study was designed as a single-center double-blind randomized controlled clinical trial. Participants were randomized into two groups receiving Vitamin C or placebo
| Arm | Type | Receives |
|---|---|---|
| Vitamin C | Experimental | Dietary Supplement: Vitamin CThe patients were given a tablet containing Vitamin C 500 mg twice a day |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboThe patients were given a placebo capsule with a similar color, shape, size and taste twice a day |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- All patients diagnosed with mild to moderate systemic lupus erythematosus (SLE).
- Patients aged over 18 years.
- Willing to participate in the study by signing an informed consent form.
Key exclusion criteria (13 listed)
- Pregnant or breastfeeding patients.
- Patients currently taking vitamin C supplementation within the past 3 days.
- Patients with other immune-related disorders, either autoimmune or immunocompromised conditions, such as Human Immunodeficiency Virus (HIV) infection.
- Patients with comorbid diseases.
- Patients diagnosed with severe SLE or those who have achieved remission.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin CThe patients received vitamin C supplementation | Dietary supplement | Vitamin C |
| PlaceboPatients received placebo capsules | Dietary supplement | Placebo |
Primary outcome
MEX-SLEDAI
Time frame: From enrollment to the end of the treatment at 8 weeks
To determine the effectiveness of adding vitamin C compared to placebo towards disease activity in SLE patients, measured with MEX-SLEDAI score
Malondialdehid
Time frame: From enrollment to the end of the treatment at 8 weeks
To determine the effectiveness of adding vitamin C compared to placebo towards malondialdehid levels concentration change in SLE patients.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2025.
- BackgroundBojanic, Z. et al. Effects of Methylprednisolone and Vitamin C Therapy on Malondialdehyde Level in Patients With Systemic Lupus Erythematosus. Acta Medica Median. 49, 10-15 (2010).
- Background: PubMed 12672194Minami Y, Sasaki T, Arai Y, Kurisu Y, Hisamichi S. Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients. J Rheumatol. 2003 Apr;30(4):747-54.
- Background: PubMed 32695177Atik N, Putri Pratiwi S, Hamijoyo L. Correlation between C-reactive Protein with Malondialdehyde in Systemic Lupus Erythematosus Patients. Int J Rheumatol. 2020 Jul 1;2020:8078412. doi: 10.1155/2020/8078412. eCollection 2020.
Related trials for Systemic Lupus Erythematosus (SLE)
RecruitingPhase 3
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
RecruitingObservational study
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Systemic Lupus Erythematosus (SLE)
Active, not recruitingPhase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
RecruitingObservational study
Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus Erythematosus
SLE - Systemic Lupus Erythematosus
RecruitingObservational study
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin C in people with Systemic Lupus Erythematosus (SLE), run by Universitas Sriwijaya at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MEX-SLEDAI (time frame: From enrollment to the end of the treatment at 8 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07083622, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025; AzTrials last refreshed its copy on 8 Nov 2026.